Developer docs
API playgroundTry for free, no card

Search company profiles

Heron Therapeutics

Full company profile

uuid0003aha

Namestring
Heron Therapeutics
Legal namestring
Heron Therapeutics, Inc.
Websiteurl
herontx.com
Company typeenum
Public
Founded yearint
1983
Descriptiontext

Heron Therapeutics is a commercial-stage biotechnology company listed on NASDAQ under the ticker HRTX that develops and markets pharmaceutical products targeting two defined care settings: acute care (postoperative pain management and surgical settings) and oncology care (chemotherapy-induced nausea and vomiting prophylaxis). The company leverages a proprietary polymer-based drug delivery technology called Biochronomer to create long-acting formulations of established active pharmaceutical ingredients, and currently markets four FDA-approved products: SUSTOL (extended-release granisetron), CINVANTI (aprepitant injectable emulsion), ZYNRELEF (bupivacaine and meloxicam extended-release solution), and APONVIE (aprepitant injectable emulsion).

The business model is built on commercial pharmaceutical product sales to institutional healthcare buyers—primarily hospital systems, ambulatory surgical centers, and oncology practices—distributed through a combination of a direct specialty sales force and channel partnerships, most notably the Cross Link Life Sciences distribution arrangement covering ZYNRELEF into orthopedic and ambulatory surgical center accounts. Net product revenue was approximately $154.9 million in 2025, and the company has set 2026 net product sales guidance of $173–183 million, supported by double-digit growth in the Acute Care franchise (ZYNRELEF and APONVIE both posting strong year-over-year growth in the second half of 2025 and early 2026). Capital allocation has emphasized commercial scaling (a planned mid-2026 field sales force expansion) and balance sheet defense in the face of a June 2026 US district court ruling invalidating key CINVANTI patents, which represents the defining near-term strategic risk to the franchise mix and equity value.

Short descriptiontext

Heron Therapeutics is a commercial-stage biotechnology company that develops and markets four FDA-approved pharmaceutical products for acute care and oncology settings, using its proprietary Biochronomer polymer drug delivery platform to sell to hospitals and surgical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCary, United States
HQ citystring
Cary
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, postoperative pain management, chemotherapy-induced nausea prevention, sustained-release drug delivery, oncology supportive care
Industry1 code
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Net Product Sales
TypeOne Time License
Description

Heron generates revenue through direct sales of its FDA-approved pharmaceutical products to healthcare providers, hospitals, and through distribution channels. Full year 2025 net product sales were approximately $154.9 million. Q1 2026 total net revenue was $34.7 million with Acute Care revenue growing 32% year-over-year.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Product pricing varies by formulation and indication
ModelOtherBilling cadencePay-as-you-go
Notes

State price disclosures are provided for Colorado, Connecticut, and Vermont prescribers with wholesale acquisition cost (WAC) and average wholesale price (AWP) information available upon request.

herontx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Biochronomer
Description

Proprietary polymer technology platform used in product development including SUSTOL and other injectable formulations.

herontx.com
Core offering1 text field

Heron Therapeutics is a commercial-stage biotechnology company that develops, manufactures, and commercializes FDA-approved pharmaceutical products for acute care and oncology patients. Its portfolio includes SUSTOL, CINVANTI, ZYNRELEF, and APONVIE, addressing postoperative pain management, chemotherapy-induced nausea and vomiting (CINV), and postoperative nausea and vomiting (PONV) using proprietary polymer-based drug delivery technologies such as Biochronomer.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ZYNRELEF demonstrated significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution (standard-of-care)
+2 more records
Product overview1 text field

Heron Therapeutics is a commercial-stage biotechnology company developing best-in-class medicines for acute care and oncology patients. The company's commercial portfolio includes four FDA-approved products: SUSTOL® (granisetron) for chemotherapy-induced nausea and vomiting (CINV), CINVANTI® (aprepitant) injectable emulsion for CINV, ZYNRELEF® (bupivacaine and meloxicam) for postoperative pain management, and APONVIE® (aprepitant) for postoperative nausea and vomiting (PONV). The Acute Care franchise focuses on pain management and PONV, while the Oncology Care franchise addresses CINV. The company's proprietary Biochronomer® polymer technology enables extended-release drug delivery. Pipeline candidates include HTX-019 for PONV and HTX-034.

Product and service6 records
1SUSTOL (granisetron) extended-release injection
CategoryOncology Supportive Care Pharmaceutical
Description

A serotonin-3 (5-HT3) receptor antagonist injectable product used in combination with other antiemetics for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults receiving MEC or AC combination chemotherapy regimens. For oncology treatment facilities and oncology healthcare providers.

2CINVANTI (aprepitant) injectable emulsion
CategoryOncology Supportive Care Pharmaceutical
Description

A substance P/neurokinin-1 (NK1) receptor antagonist injectable emulsion used in adults for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with highly emetogenic (HEC) and moderately emetogenic (MEC) chemotherapy. Administered as 30-minute IV infusion or 2-minute IV injection without polysorbate 80 or synthetic surfactants. For oncology healthcare providers.

3ZYNRELEF (bupivacaine and meloxicam) extended-release solution
CategoryAcute Care Pharmaceutical
Description

The first and only dual-acting local anesthetic delivering a fixed-dose combination of bupivacaine and the NSAID meloxicam, approved for postoperative analgesia for up to 72 hours after soft tissue and orthopedic surgical procedures. Demonstrated significant pain reduction and increased proportion of opioid-free patients in Phase 3 studies. For surgeons, anesthesiologists, hospitals, and ambulatory surgical centers.

4APONVIE (aprepitant) injectable emulsion
CategoryAcute Care Pharmaceutical
Description

A neurokinin-1 (NK1) receptor antagonist administered as a 30-second IV injection of aprepitant for the prevention of postoperative nausea and vomiting (PONV) in adults. For surgical centers, hospitals, and perioperative care teams.

5HTX-019
CategoryPipeline Pharmaceutical Candidate
Description

A development-stage product candidate for postoperative nausea and vomiting (PONV) prevention, being advanced by Heron's pipeline.

6HTX-034
CategoryPipeline Pharmaceutical Candidate
Description

A pipeline product candidate listed on Heron's patent information page; specific therapeutic indication details were not provided in available source material.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-01-01
Description

Heron Therapeutics partnered with Cross Link Life Sciences in January 2024 to expand distribution of Zynrelef, its pain management treatment for orthopedic surgery patients. The partnership aims to increase geographic reach and accessibility of ZYNRELEF in the surgical market.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Heron reached a settlement with Baxter Healthcare Corporation in CINVANTI patent litigation, with the U.S. District Court for the District of Delaware dismissing the pending case on April 28, 2026.

Strategic tierMinorTypeOthers
Description

Azurity Pharmaceuticals was the opposing party in patent litigation regarding CINVANTI patents. The U.S. District Court ruled in favor of Azurity, invalidating certain Heron patent claims (US Patent Nos. 12,115,255 and 12,290,520). Heron stated it plans to appeal the decision to the U.S. Court of Appeals for the Federal Circuit.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Tarsus is a commercial-stage specialty pharmaceutical company with a focused single-asset-to-multi-product launch strategy. Its stage and specialty commercialization profile are comparable to Heron's, although it operates in a different therapeutic area (ophthalmology).

TypeDirect peer
Description

Cara Therapeutics is a specialty pharmaceutical company developing therapeutics for pain and pruritus, including a hospital-based acute care franchise. Its therapeutic focus on pain/itch and similar commercial-stage specialty pharma profile make it a relevant comparable to Heron.

TypeEmerging player
Description

Apellis is a commercial-stage specialty biotech with a focused therapeutic portfolio and recent product launches. While not directly competing with Heron's products, it shares the profile of a recently commercial, narrowly focused specialty pharmaceutical company navigating similar scaling and reimbursement dynamics.

TypeDirect peer
Description

Collegium is a specialty pharmaceutical company focused on responsible pain management, including abuse-deterrent opioid formulations and non-opioid pain therapies. It overlaps with Heron's ZYNRELEF positioning around opioid-sparing postoperative pain management and shares a similar commercial-stage specialty pharma profile.

TypeBroad incumbent
Description

Salix is a large specialty pharmaceutical company focused on gastroenterology with a strong US sales force targeting hospital and specialty physicians. While its therapeutic focus differs, its commercial-stage specialty pharma model and hospital sales motion are highly comparable to Heron (and is the former employer of Heron's CDO).

TypeDirect peer
Description

Pacira's Exparel (long-acting bupivacaine) competes directly with Heron's ZYNRELEF in the postoperative local analgesia market. Both companies target hospital and surgical center customers with extended-release injectable anesthetics, making Pacira Heron's most direct commercial-stage competitor.

TypeEmerging player
Description

Osmotica is a specialty pharmaceutical company with branded neurology and hospital-adjacent products, sharing Heron's profile as a smaller specialty pharma commercializing differentiated branded products to healthcare providers in the US.

TypeBroad incumbent
Description

Bausch Health is a large diversified specialty pharmaceutical company with presence in hospital-administered and specialty therapeutics. Its scale, infrastructure and broader portfolio make it a broad incumbent comparable to Heron's specialty pharma commercial model rather than a direct competitor.

TypeDirect peer
Description

Eagle Pharmaceuticals is a specialty pharma company with oncology supportive care and hospital-based injectable products, and has expanded into the PONV space via its acquisition of Acacia Pharma (Barhemsys). Its portfolio and acute-care hospital channel overlap meaningfully with Heron's CINVANTI and APONVIE franchises.

TypeDirect peer
Description

Acacia developed Barhemsys (amisulpride) for postoperative nausea and vomiting, making it a direct head-to-head competitor of Heron's APONVIE in the PONV indication. Acacia is now part of Eagle Pharmaceuticals but its product competes with Heron in the same surgical hospital channel.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Heron Therapeutics

Specialty Pharmaceuticalsherontx.com

Heron Therapeutics is a commercial-stage biotechnology company that develops and markets four FDA-approved pharmaceutical products for acute care and oncology settings, using its proprietary Biochronomer polymer drug delivery platform to sell to hospitals and surgical centers.

What Heron Therapeutics does

Heron Therapeutics is a commercial-stage biotechnology company listed on NASDAQ under the ticker HRTX that develops and markets pharmaceutical products targeting two defined care settings: acute care (postoperative pain management and surgical settings) and oncology care (chemotherapy-induced nausea and vomiting prophylaxis). The company leverages a proprietary polymer-based drug delivery technology called Biochronomer to create long-acting formulations of established active pharmaceutical ingredients, and currently markets four FDA-approved products: SUSTOL (extended-release granisetron), CINVANTI (aprepitant injectable emulsion), ZYNRELEF (bupivacaine and meloxicam extended-release solution), and APONVIE (aprepitant injectable emulsion).

The business model is built on commercial pharmaceutical product sales to institutional healthcare buyers—primarily hospital systems, ambulatory surgical centers, and oncology practices—distributed through a combination of a direct specialty sales force and channel partnerships, most notably the Cross Link Life Sciences distribution arrangement covering ZYNRELEF into orthopedic and ambulatory surgical center accounts. Net product revenue was approximately $154.9 million in 2025, and the company has set 2026 net product sales guidance of $173–183 million, supported by double-digit growth in the Acute Care franchise (ZYNRELEF and APONVIE both posting strong year-over-year growth in the second half of 2025 and early 2026). Capital allocation has emphasized commercial scaling (a planned mid-2026 field sales force expansion) and balance sheet defense in the face of a June 2026 US district court ruling invalidating key CINVANTI patents, which represents the defining near-term strategic risk to the franchise mix and equity value.

Heron Therapeutics firmographics

Firmographics
Name
Heron Therapeutics
Legal name
Heron Therapeutics, Inc.
Website
https://herontx.com
Company type
Public
Founded year
1983
Operating status
Operating
Headcount range
101–250 employees
Short description
Heron Therapeutics is a commercial-stage biotechnology company that develops and markets four FDA-approved pharmaceutical products for acute care and oncology settings, using its proprietary Biochronomer polymer drug delivery platform to sell to hospitals and surgical centers.
Ownership category
akta.pro rank

Heron Therapeutics industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Specialty pharmaceuticals
  • Postoperative pain management
  • Chemotherapy-induced nausea prevention
  • Sustained-release drug delivery
  • Oncology supportive care

Where Heron Therapeutics is headquartered

Location

Headquarters

HQ city
Cary
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Heron Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Net Product Sales: Heron generates revenue through direct sales of its FDA-approved pharmaceutical products to healthcare providers, hospitals, and through distribution channels. Full year 2025 net product sales were approximately $154.9 million. Q1 2026 total net revenue was $34.7 million with Acute Care revenue growing 32% year-over-year.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goProduct pricing varies by formulation and indication

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Heron Therapeutics product offering

Product offering

Core offering

Heron Therapeutics is a commercial-stage biotechnology company that develops, manufactures, and commercializes FDA-approved pharmaceutical products for acute care and oncology patients. Its portfolio includes SUSTOL, CINVANTI, ZYNRELEF, and APONVIE, addressing postoperative pain management, chemotherapy-induced nausea and vomiting (CINV), and postoperative nausea and vomiting (PONV) using proprietary polymer-based drug delivery technologies such as Biochronomer.

Product overview

Heron Therapeutics is a commercial-stage biotechnology company developing best-in-class medicines for acute care and oncology patients. The company's commercial portfolio includes four FDA-approved products: SUSTOL® (granisetron) for chemotherapy-induced nausea and vomiting (CINV), CINVANTI® (aprepitant) injectable emulsion for CINV, ZYNRELEF® (bupivacaine and meloxicam) for postoperative pain management, and APONVIE® (aprepitant) for postoperative nausea and vomiting (PONV). The Acute Care franchise focuses on pain management and PONV, while the Oncology Care franchise addresses CINV. The company's proprietary Biochronomer® polymer technology enables extended-release drug delivery. Pipeline candidates include HTX-019 for PONV and HTX-034.

Differentiator

Problem solved

Functional benefit

Brands

  • Biochronomer: Proprietary polymer technology platform used in product development including SUSTOL and other injectable formulations.

Products and services

  • SUSTOL (granisetron) extended-release injection A serotonin-3 (5-HT3) receptor antagonist injectable product used in combination with other antiemetics for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults receiving MEC or AC combination chemotherapy regimens. For oncology treatment facilities and oncology healthcare providers.
  • CINVANTI (aprepitant) injectable emulsion A substance P/neurokinin-1 (NK1) receptor antagonist injectable emulsion used in adults for the prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with highly emetogenic (HEC) and moderately emetogenic (MEC) chemotherapy. Administered as 30-minute IV infusion or 2-minute IV injection without polysorbate 80 or synthetic surfactants. For oncology healthcare providers.
  • ZYNRELEF (bupivacaine and meloxicam) extended-release solution The first and only dual-acting local anesthetic delivering a fixed-dose combination of bupivacaine and the NSAID meloxicam, approved for postoperative analgesia for up to 72 hours after soft tissue and orthopedic surgical procedures. Demonstrated significant pain reduction and increased proportion of opioid-free patients in Phase 3 studies. For surgeons, anesthesiologists, hospitals, and ambulatory surgical centers.
  • APONVIE (aprepitant) injectable emulsion A neurokinin-1 (NK1) receptor antagonist administered as a 30-second IV injection of aprepitant for the prevention of postoperative nausea and vomiting (PONV) in adults. For surgical centers, hospitals, and perioperative care teams.
  • HTX-019 A development-stage product candidate for postoperative nausea and vomiting (PONV) prevention, being advanced by Heron's pipeline.
  • HTX-034 A pipeline product candidate listed on Heron's patent information page; specific therapeutic indication details were not provided in available source material.

Quantifiable outcome

  • ZYNRELEF demonstrated significantly reduced pain and significantly increased proportion of patients requiring no opioids through the first 72 hours following surgery compared to bupivacaine solution (standard-of-care)
  • +2 more outcomes

Companies that use Heron Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Heron Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Heron Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Cross Link Life SciencescoreChannel Partner/ Reseller/ Distributor · 1 January 2024Heron Therapeutics partnered with Cross Link Life Sciences in January 2024 to expand distribution of Zynrelef, its pain management treatment for orthopedic surgery patients. The partnership aims to increase geographic reach and accessibility of ZYNRELEF in the surgical market.
  • Baxter Healthcare CorporationminorStrategic or Co-development PartnerHeron reached a settlement with Baxter Healthcare Corporation in CINVANTI patent litigation, with the U.S. District Court for the District of Delaware dismissing the pending case on April 28, 2026.
  • Azurity PharmaceuticalsminorOthersAzurity Pharmaceuticals was the opposing party in patent litigation regarding CINVANTI patents. The U.S. District Court ruled in favor of Azurity, invalidating certain Heron patent claims (US Patent Nos. 12,115,255 and 12,290,520). Heron stated it plans to appeal the decision to the U.S. Court of Appeals for the Federal Circuit.

Scale indicators13 records

Recent moves6 records

Expansion highlights5 records

Heron Therapeutics competitors and assessment

Company assessment

Emerging players

  • Tarsus Pharmaceuticals: Tarsus is a commercial-stage specialty pharmaceutical company with a focused single-asset-to-multi-product launch strategy. Its stage and specialty commercialization profile are comparable to Heron's, although it operates in a different therapeutic area (ophthalmology).
  • Apellis Pharmaceuticals: Apellis is a commercial-stage specialty biotech with a focused therapeutic portfolio and recent product launches. While not directly competing with Heron's products, it shares the profile of a recently commercial, narrowly focused specialty pharmaceutical company navigating similar scaling and reimbursement dynamics.
  • Osmotica Pharmaceutical: Osmotica is a specialty pharmaceutical company with branded neurology and hospital-adjacent products, sharing Heron's profile as a smaller specialty pharma commercializing differentiated branded products to healthcare providers in the US.

Direct peers

  • Cara Therapeutics: Cara Therapeutics is a specialty pharmaceutical company developing therapeutics for pain and pruritus, including a hospital-based acute care franchise. Its therapeutic focus on pain/itch and similar commercial-stage specialty pharma profile make it a relevant comparable to Heron.
  • Collegium Pharmaceutical: Collegium is a specialty pharmaceutical company focused on responsible pain management, including abuse-deterrent opioid formulations and non-opioid pain therapies. It overlaps with Heron's ZYNRELEF positioning around opioid-sparing postoperative pain management and shares a similar commercial-stage specialty pharma profile.
  • Pacira BioSciences: Pacira's Exparel (long-acting bupivacaine) competes directly with Heron's ZYNRELEF in the postoperative local analgesia market. Both companies target hospital and surgical center customers with extended-release injectable anesthetics, making Pacira Heron's most direct commercial-stage competitor.
  • Eagle Pharmaceuticals: Eagle Pharmaceuticals is a specialty pharma company with oncology supportive care and hospital-based injectable products, and has expanded into the PONV space via its acquisition of Acacia Pharma (Barhemsys). Its portfolio and acute-care hospital channel overlap meaningfully with Heron's CINVANTI and APONVIE franchises.
  • Acacia Pharma (Eagle subsidiary): Acacia developed Barhemsys (amisulpride) for postoperative nausea and vomiting, making it a direct head-to-head competitor of Heron's APONVIE in the PONV indication. Acacia is now part of Eagle Pharmaceuticals but its product competes with Heron in the same surgical hospital channel.

Broad incumbents

  • Salix Pharmaceuticals: Salix is a large specialty pharmaceutical company focused on gastroenterology with a strong US sales force targeting hospital and specialty physicians. While its therapeutic focus differs, its commercial-stage specialty pharma model and hospital sales motion are highly comparable to Heron (and is the former employer of Heron's CDO).
  • Bausch Health: Bausch Health is a large diversified specialty pharmaceutical company with presence in hospital-administered and specialty therapeutics. Its scale, infrastructure and broader portfolio make it a broad incumbent comparable to Heron's specialty pharma commercial model rather than a direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Heron Therapeutics compliance and trust

Trust signal

Compliance4 records

Heron Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Heron Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Heron Therapeutics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Heron Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heron Therapeutics

What does Heron Therapeutics do?

Heron Therapeutics is a commercial-stage biotechnology company that develops, manufactures, and commercializes FDA-approved pharmaceutical products for acute care and oncology patients. Its portfolio includes SUSTOL, CINVANTI, ZYNRELEF, and APONVIE, addressing postoperative pain management, chemotherapy-induced nausea and vomiting (CINV), and postoperative nausea and vomiting (PONV) using proprietary polymer-based drug delivery technologies such as Biochronomer.

Is Heron Therapeutics a public or private company?

Heron Therapeutics is a public company. It is classified as public and is currently operating.

When was Heron Therapeutics founded?

Heron Therapeutics was founded in 1983. It employs 101 to 250 people.

Where is Heron Therapeutics based?

Heron Therapeutics is headquartered in Cary, United States, in the North America region.

How does Heron Therapeutics make money?

One revenue line is on record: net Product Sales.

Who are Heron Therapeutics's main competitors?

Emerging players on record are Tarsus Pharmaceuticals, Apellis Pharmaceuticals and Osmotica Pharmaceutical. Direct peers are Cara Therapeutics, Collegium Pharmaceutical, Pacira BioSciences, Eagle Pharmaceuticals and Acacia Pharma (Eagle subsidiary). Broad incumbents are Salix Pharmaceuticals and Bausch Health.

Does Heron Therapeutics have an API?

No public API is recorded for Heron Therapeutics.

What industry is Heron Therapeutics in?

Heron Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewCorMedix Reports $54.5M Q3 Revenue, Raises EBITDA Guidance and Advances Heron DealCorMedix reported Q3 2026 revenue of $54.5 million and narrowed full-year adjusted EBITDA guidance to $130–140 million. The company expects its Heron acquisition to close in Q1 2027, with pro forma 2027 revenue of $125–150 million and annualized cost synergies of $45–60 million.The Motley FoolCorMedix (CRMD) Q3 2026 Earnings Call TranscriptCorMedix reported Q3 2026 consolidated revenue of $54.5 million, down from $104.3 million a year earlier, due to lower DefenCath pricing after the TDAPA transition. The company reaffirmed full-year 2026 revenue guidance of $325–345 million and narrowed adjusted EBITDA guidance to $130–140 million. It also announced the acquisition of Heron Therapeutics assets, expected to contribute $125–150 million in pro forma 2027 revenue.Seeking AlphaHeron Therapeutics, Inc. (HRTX) M&A Call TranscriptCorMedix and Heron Therapeutics announced a definitive asset purchase agreement under which CorMedix will acquire substantially all of Heron's assets. The call was led by CorMedix CEO Joe Todisco, with CFO Susan Blum and other executives joining for Q&A.YahooCRMD to Acquire HRTX Assets for $223M Upfront to Expand PortfolioCorMedix agreed to acquire Heron Therapeutics' assets for $223M upfront, adding four commercial-stage products. The deal includes earn-outs and a 5% royalty, with expected annualized cost synergies of $45-60M by 2027. Closing is expected in Q1 2027.The future of tradingHeron Therapeutics Q3 Net Product Sales USD 35.25 MillionHeron Therapeutics reported Q3 net product sales of USD 35.25 million and an EPS of -0.03. The company's stock is tracked on major exchanges, with share prices indicative and subject to market fluctuations.ChartmillHeron Therapeutics (NASDAQ:HRTX) Q3 Revenue Misses Estimates as CorMedix Asset Deal Lifts SharesHeron Therapeutics reported Q3 2026 net revenue of $35.3 million, missing the $38.3 million estimate, and a non-GAAP loss of $0.03 per share. The company also disclosed a definitive agreement for CorMedix to acquire substantially all of its assets. No financial guidance was provided.Quiver QuantitativeHERON THERAPEUTICS ($HRTX) Releases Q3 2026 Earnings | HRTX Stock NewsHERON THERAPEUTICS reported Q3 2026 earnings of -$0.03 per share, missing estimates by $0.00, and revenue of $35.25 million, missing estimates by $3 million. The company also saw 69 institutional investors add shares and 69 decrease positions in the most recent quarter.YahooCorMedix stock gains as Heron deal adds four productsCorMedix agreed to acquire Heron Therapeutics for about $222.6 million, adding four commercial-stage products to its hospital and acute-care platform. The deal includes $145 million in cash, 14.58 million shares, and earn-out payments, with expected operating cost synergies of $45-60 million annually by 2027.The future of tradingHeron Therapeutics Q3 net revenue falls 7.8%, to sell all assets to CorMedixHeron Therapeutics reported Q3 net revenue of $35.25 million, down 7.8% year-over-year. The company agreed to sell substantially all assets to CorMedix, pending shareholder approval, and withdrew its full-year 2026 guidance in August.Investing.comCorMedix stock gains as Heron deal adds four productsCorMedix agreed to acquire Heron Therapeutics' assets for about $222.6 million, adding four commercial-stage products to its hospital and acute-care platform. The deal includes $145 million in cash, stock consideration, and earn-out payments, with expected operating cost synergies of $45-60 million annually by 2027.